Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 17/20 | 0.59 |
| ▸ | SELP | P16109 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14557942 | 1.00 | SELE (0.59) | SELESELP | |
| SCHEMBL15839391 | 0.93 | SELE (0.51) | SELESELP | |
| SCHEMBL22247226 | 0.92 | SELE (0.54) | SELESELP | |
| SCHEMBL15839394 | 0.92 | SELE (0.54) | SELESELP | |
| SCHEMBL22821431 | 0.91 | SELE (0.53) | SELESELP | |
| SCHEMBL22821644 | 0.91 | SELE (0.52) | SELESELP | |
| SCHEMBL22821246 | 0.90 | SELE (0.55) | SELESELP | |
| SCHEMBL22821627 | 0.90 | SELE (0.52) | SELESELP | |
| SCHEMBL22821337 | 0.90 | SELE (0.54) | SELESELP | |
| SCHEMBL22821536 | 0.90 | SELE (0.51) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | GLYCOMIMETICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | SELE 5/4885SELP 10/4885 |
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | LGALS3, LGALS3BP, LGALS1 | SELE 5/4885SELP 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.